. 2013 Apr;20(2):52–58. doi: 10.5214/ans.0972.7531.200205

Table 2: Infusion characteristics for a proposed gene therapy trial for the treatment of Parkinson’s disease with CED delivery of AAV2-GDNF using the MRI interventions SmartFlow^® neurocatheter system.

Proposed Protocol for Gene Therapy CED to the Putamen
Variable	Value
Infusion location	Putamen
Incision	Cranial Vertex
Patient position	Semi-sitting, “beach chair”
Posterior Infusion site	150 microliters
Anterior Infusion site	300 microliters
Proposed initial infusion rate	1.0 microliters / minute (0.06 mL/hr)
Proposed maximum infusion rate	5.0 microliters / minute (0.3 mL/hr)

Table 2: Infusion characteristics for a proposed gene therapy trial for the treatment of Parkinson’s disease with CED delivery of AAV2-GDNF using the MRI interventions SmartFlow® neurocatheter system.